Vitamin A supplement for stem cell transplant patients
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether giving vitamin A by mouth to adults before and after a stem cell transplant can help their recovery. The goal is to see if it reduces complications and improves overall outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are scheduled for a stem cell transplant using donor cells (allogeneic).
- Your vitamin A levels are within the normal range for your age.
- You can take medicine by mouth (swallowing).
- Your liver function tests (bilirubin, AST, ALT) are not too high.
- You will receive stem cells from a donor's blood (peripheral blood stem cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking vitamin A and D after a stem cell transplant can help improve recovery. It is for people with certain blood cancers who have a matched donor and are in remission or have low disease activity.
This trial tests whether adding vitamin C to standard steroid treatment helps control gut graft-versus-host disease (GVHD) after a stem cell transplant. It aims to reduce inflammation and improve symptoms with a treatment that is generally well-tolerated.
This trial tests whether omega-3 fatty acids can help prevent acute graft-versus-host disease (aGVHD) in people receiving a stem cell transplant from a donor. Omega-3 may reduce inflammation and lower the chance of this serious complication.
This study tests whether taking an antioxidant called NAC before a half-matched stem cell transplant helps platelets (the cells that help blood clot) recover faster in people with aplastic anemia. If you qualify, you may get NAC or a placebo, and the trial will see if it improves your recovery.
This study tests a combination of three drugs (cyclophosphamide, sirolimus, and VIC-1911) to prevent graft-versus-host disease (GVHD), a common complication after a stem cell transplant. It is for children aged 8-18 with certain blood diseases who are undergoing a haploidentical stem cell transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.